EBD-GROUP
The sixth annual EuroMedtech™ partnering conference will be held May 7–8, 2014 in Linz, Austria.
EuroMedtech is Europe's leading medical technology partnering conference, providing collaboration opportunities to medtech decision makers and investors.
The Presenting Companies track provides a pipeline to innovative companies interested in partnering their technologies or products, initiating strategic alliances, or tapping into the international financing network. In addition, early stage projects and small entrepreneurial companies can present their novel ideas to large medtech, pharma, and investors in the Next Generation track.
A preliminary list of presenting companies has just been released, and includes industry innovators such as Acarix A/S; AFreeze; Avalon Health Economics; CiToxLAB Scantox; ConsulTech GmbH; CVTEC; Humedics GmbH; Implandata Ophthalmic Products GmbH; ImPress MedTech e.U.; Inventram/Tarabios; iSTAR Medical SA; J A Kemp; Johns Hopkins University; LevOss; LIVEcheck - Global Diagnostics; Michelson Diagnostics Ltd; Reapplix; Sagentia; Senzime; Sheltagen Medical Ltd; Software Quality Lab GmbH; Transcatheter Technologies GmbH.
“iSTAR has introduced an innovative ophthalmic implant made from STAR® Biomaterial and has partnered with international distributors that were initially met at EuroMedtech 2012,” said Michel Alvarez, CEO of iSTAR Medical . “Presenting again will put us in front of new potential partners and investors interested in our current product and our robust development pipeline.”
“There is a huge market demand for technologies to treat chronic wounds, particularly diabetic wounds,” said Niels Erik Holm, Founder and CEO of Reapplix . “Our expected exit time is past the completion of our Randomized Controlled Trial, however, in the meantime we would like to discuss market access/reimbursement and commercialization strategies with potential partners. EuroMedtech puts us in front of the right people.”
Produced by EBD Group, EuroMedtech caters to companies involved in all parts of the advanced medical technology industry, from those serving mainline therapeutic categories such as drug delivery and augmented intervention in medicine, through diagnostics, imaging and eHealth to those involved in platform technologies such as micro and nanotechnological tools and implantable devices.
The 2013 event attracted 261 dealmakers from 191 companies who participated in 600 one-to-one meetings. The event also featured presentations by 44 of the most exciting medtech companies in Europe.
Presentation and registration information for EuroMedtech 2014 is available online. Registration closes May 5, 2014, 18:00 CET , after which all registrations will be handled on site.
Follow EuroMedtech on Twitter: @EuroMedtech , hashtag No. EMT14.
Or join the Medtech Industry Group on partnering360® to kick off your partnering activities before EuroMedtech, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round. Join the vibrant community of medtech companies on partnerning360 today.
About the Health Technology Cluster
The Health Technology Cluster (HC) is an inter-sectoral network for increasing innovative capacity and international competitiveness of Health Technology companies, their suppliers as well as relevant research and healthcare facilities. The HC currently connect 220 partner companies from Austria and South Germany. Due to the Upper Austrian strength in medical technology, the main focus is on medical electronics, software, clean room & hygiene, hospital equipment, end-user products, diagnostics-pharma and materials (metal/plastics). More detailed information under www.gesundheitstechnologie-cluster.at .
Please find the digital version under www.gesundheitstechnologie-cluster.at/presse
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140422005693/en/
Contact:
Media-Contact:
Communication Health Technology Cluster (Clusterland
Oberösterreich GmbH)
Stephanie Rieß, M.A., +43 732 79810 5158
stephanie.riess@clusterland.at
or
EBD
Group
Erin Righetti, 760-930-0500
erighetti@ebdgroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum